Navigation path

Additional tools

    Profile of registrant


Identification number in the register: 7990322925-77
Registration date: 06/01/2009 16:12:35

The information on this entity was last modified on: 20/01/2015 10:06:56
The date of the last annual update was: 05/01/2015 14:52:18

This entry follows the format of the previous Register. It will be changed to the new format when the entity makes the next update.
Next update due latest on: 27/04/2015

    Registrant : Organisation or self-employed individual




    Section of registration

II - In-house lobbyists and trade/professional associations

Companies & groups

    Contact details

Great West Road, 980
Brentford, Middlesex TW8 9GS

(+44) 20 8047 5000


Contact details of Brussels office:

Kunstlaan 46 Avenue Des Arts
1000 Brussels

Tel: +32 (0) 2 282 40 55

    Person with legal responsibility

Mr  Andrew Witty

Chief Executive Officer

    Person in charge of EU relations

Ms  Sue Middleton

Vice President European Government Affairs

    Goals / remit

GlaxoSmithKline (GSK) is a research-based pharmaceutical company. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.

Headquartered in the UK, we are one of the industry leaders with an estimated seven per cent of the world's pharmaceutical market. We produce medicines that treat major disease areas, including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions, and we market over 25 vaccines to protect against illnesses such as hepatitis A and B, diphtheria, tetanus,whooping cough, typhoid and influenza. GSK also produce consumer health care products including, over-the-counter (OTC) medicines, dental products, smoking control products and nutritional healthcare drinks.

We believe we are the only pharmaceutical company researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria. In 2007, our total community investment was valued at £282 million, equivalent to 3.8 per cent of Group total profit before tax.



- to adress unmet medical needs, improve patient safety and strengthen disease prevention in Europe
- to increase Europe´s competitiveness as a location for Research and Development investment

    Number of persons involved in the activities described in the box above


The number of persons reflect the full time employement falling under the scope of the register.

    Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Paulus Lambertus Antonius van Hoof 02/08/2014 31/07/2015
Sophie Renee Jeanne Marie Philippine Crousse 03/09/2014 28/08/2015
Karin Jeanette Drielsma 06/08/2014 04/08/2015
Guilherme Monteiro Ferreira Borges Dos Santos 30/09/2014 26/09/2015
Diana Mereu 04/10/2014 02/10/2015
Christian Baracat 26/08/2014 19/08/2015
Gisela Payeras Bailly 26/08/2014 19/08/2015
Nicholas Collinge Crosby 08/10/2014 06/10/2015

    Fields of interest

  • Competition
  • Consumer Affairs
  • Employment and Social Affairs
  • Enterprise
  • Humanitarian Aid
  • Internal Market
  • Public Health
  • Research and Technology
  • Trade

    Membership and affiliation

EFPIA - European Federation of Pharmaceutical Industries and Associations
Cosmetics Europe

    Financial data

01/2013  -  12/2013

600,000  € - 700,000  €

0 €

0 €

In 2013, costs associated with lobbying of EU institutions were in the range of 600.000-700.000 euros. This figure is calculated based on the Interinstitutional Agreements published in the Official Journal of 22 July 2011 and includes:
•A percentage of the salaries of the staffers falling under the scope of the Register
•A percentage of the overall costs of running an office in Brussels
•100% of GSK spend on conferences dedicated to “EU Public Affairs”
•A percentage of the costs incurred by the staffers falling under the scope of the Register for travel and accommodation related to EU Public Affairs activities
•100% of the consulting cost spent on EU Public Affairs advice.
In order to avoid double reporting on the Register, this figure excludes trade association membership fees as responsibility for declaring these lies with the respective organisations. The 2013 figure is smaller than GSK’s 2012 figure because there were vacancies. The 2013 figure is 217000 euros.

    Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.

The organisation has also declared to be bound to the following other Code: